Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

Nir Peled, Waleed Kian, Edna Inbar, Iris M. Goldstein, Melanie Zemel, Ofer Rotem, Anna B. Rozenblum, Hovav Nechushtan, Elizabeth Dudnik, Daniel Levin, Alona Zer, Shoshana Keren-Rosenberg, Shlomit Yust-Katz, Vered Fuchs, Areen A. Remilah, Ilan Shelef, Laila C. Roisman

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study'. Together they form a unique fingerprint.

Keyphrases

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science